The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Reduced intravenous glutathione in the treatment of early parkinson's disease
Abstract
1. Several studies have demonstrated a deficiency in reduced glutathione (GSH) in the nigra of patients with Parkinson's Disease (PD). In particular, the magnitude of reduction in GSH seems to parallel the severity of the disease. This finding may indicate a means by which the nigra cells could be therapeutically supported. 2. The authors studied the effects of GSH in nine patients with early, untreated PD. GSH was administered intravenous, 600 mg twice daily, for 30 days, in an open label fashion. Then, the drug was discontinued and a follow-up examination carried-out at 1-month interval for 2-4 months. Thereafter, the patients were treated with carbidopa-levodopa. 3. The clinical disability was assessed by using two different rating scale and the Webster Step-Second Test at baseline and at 1-month interval for 4-6 months. All patients improved significantly after GSH therapy, with a 42% decline in disability. Once GSH was stopped the therapeutic effect lasted for 2-4 months. 4. Our data indicate that in untreated PD patients GSH has symptomatic efficacy and possibly retards the progression of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GSH therapy improved performance of patients, with nearly half a decline in disability lasting about three months after interrupted therapy.
“GSH therapy improved the performance of patients, with nearly half a decline in disability of patients which lasted for about three months after interrupted therapy.”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Sechi et al. 1996
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Ehringer, H., & Hornykiewicz, O. (1960) · Journal of Molecular Medicine · doi:10.1007/bf01485901 · Cited by 1,875
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Glutathione and Related γ-Glutamyl Compounds: Biosynthesis and Utilization
Meister, A., & Tate, S. S. (1976) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.45.070176.003015 · Cited by 839
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753
Treatment of parkinsonism with levodopa.
Yahr, M., Duvoisin, R., Schear, M., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 619
Critical analysis of the disability in Parkinson's disease.
Webster, D. D. (1968) · PubMed · Cited by 488
Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes
Volterra, A., Trotti, D., Tromba, C., FLORIDI, S., & Racagni, G. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02924.1994 · Cited by 457
New insights into the cause of Parkinson's disease
Jenner, P., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Neurology · doi:10.1212/wnl.42.12.2241 · Cited by 272
Blood-Brain Barrier Restriction of Peptides and the Low Uptake of Enkephalins*
Cornford, E. M., Braun, L. D., Crane, P. D., & Oldendorf, W. H. (1978) · Endocrinology · doi:10.1210/endo-103-4-1297 · Cited by 220
Selegiline as initial treatment in de novo parkinsonian patients
Myllylä, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1992) · Neurology · doi:10.1212/wnl.42.2.339 · Cited by 171
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
Jenner, P. G. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00013.x · Cited by 163
Blood-Brain Barrier: Interface Between Internal Medicine and the Brain
Pardridge, W. M., OLDENDORF, W. H., CANCILLA, P., & FRANK, H. J. L. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-82 · Cited by 160
Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease
Tooyama, I., Kawamata, T., Walker, D., Yamada, T., Hanai, K., Kimura, H., Iwane, M., Igarashi, K., McGeer, E. G., & McGeer, P. L. (1993) · Neurology · doi:10.1212/wnl.43.2.372 · Cited by 114
The protective influence of the locus ceruleus on the blood‐brain barrier
Harik, S. I., & McGunigal, T. (1984) · Annals of Neurology · doi:10.1002/ana.410150609 · Cited by 94
Evidence for Transcapillary Transport of Reduced Glutathione in Vascular Perfused Guinea-Pig Brain
Zloković, B. V., Mačkić, J. B., McComb, J. G., Weiss, M. H., Kaplowitz, N., & Kannan, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1715 · Cited by 63
Teychenné, P. F., Bergsrud, D., Racy, A., et al. (1982) · Neurology · doi:10.1212/wnl.32.6.577 · Cited by 62
Neuropathology of the locus ceruleus: a semi-quantitative study
Tomonaga, M. (1983) · Journal of Neurology · doi:10.1007/bf00313699 · Cited by 61
Flagged first, then by citations
Research works printed but not linked: 2
- Mcneil, 1986, Glutathione depletion mimics MPTP neurotoxicity and age-correlated changes in dopamine neurons in substantia nigra of the C 57BL/6NNia mouse, Soc for Neuroscience Abstracts 12
- Sian, 1992, Glutathione levels in brain neurodegenerative diseases affecting basal ganglia, Br J Pharmacol, 106, 118
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Oxidative Stress in Neurodegenerative Diseases
Simonian, N. A., & Coyle, J. T. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.000503 · Cited by 1,377
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
Neumann, U., Derwenskus, F., Flaiz Flister, V., Schmid-Staiger, U., Hirth, T., & Bischoff, S. (2019) · Antioxidants · doi:10.3390/antiox8060183 · Cited by 154
Chinta, S. J., Kumar, M. J., Hsu, M., Rajagopalan, S., Kaur, D., Rane, A., Nicholls, D. G., Choi, J., & Andersen, J. K. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3885-07.2007 · Cited by 145
Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
Precision Redox: The Key for Antioxidant Pharmacology
Meng, J., Lv, Z., Zhang, Y., Wang, Y., Qiao, X., Sun, C., Chen, Y., Guo, M., Han, W., Ye, A., et al. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8212 · Cited by 122
Sikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70
Metadata
- Authors
- Sechi, G., Deledda, M. G., Bua, G., Satta, W. M., Deiana, G. A., Pes, G. M., & Rosati, G.
- Affiliations
- University of Sassari (IT)
- Corresponding author
- Sechi, Gianpietro
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 1996-10
- Volume
- 20
- Issue
- 7
- Pages
- 1159-1170
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W1970034280
- Cited by
- 173
- References
- 19
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 10 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 12 · 2019: 5 · 2018: 2 · 2017: 10 · 2016: 5 · 2015: 8 · 2014: 7 · 2013: 4 · 2012: 9
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- Parkinson's disease, reduced glutathione, substantia nigra, oxidative stress, levodopa/carbidopa, functional disability, disease progression
- MeSH terms
- Aged, Female, Glutathione, Humans, Injections, Intravenous, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease, Tremor, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
